Item 8.01 Other Events.
On March 26, 2021, bluebird bio, Inc. ("bluebird") and Bristol Myers Squibb
Company issued a press release announcing that the U.S. Food and Drug
Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) as
the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor
(CAR) T cell immunotherapy for the treatment of adults with multiple myeloma who
have received at least four prior therapies, including an immunomodulatory
agent, a proteasome inhibitor, and an anti-CD38 antibody. Abecma is being
jointly developed and commercialized in the U.S. as part of a Co-Development,
Co-Promotion and Profit Share Agreement between Bristol Myers Squibb and
bluebird.
The full text of bluebird's press release regarding this announcement is filed
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by bluebird bio, Inc. on March 26, 2021 .
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses